Literature DB >> 15614251

Value of an enzymatic assay for the determination of serum ceruloplasmin.

Georgina Macintyre1, Klaus S Gutfreund, W R Wayne Martin, Richard Camicioli, Diane W Cox.   

Abstract

The serum concentration of the copper protein ceruloplasmin has been an important diagnostic indicator of Wilson's disease (WD). It is widely quoted that 95% of people with WD have low serum ceruloplasmin concentrations. Current evidence suggests that a normal serum ceruloplasmin concentration is more common in patients with WD, particularly those with liver disease, perhaps in part because of the routine use of an immunologic assay. This assay might indicate a normal level of ceruloplasmin when the enzymatic activity is lower. Enzymatic activity is the biologically relevant parameter. We compared the immunologic measurement with the enzymatic assessment of oxidase activity in patients with liver or neurologic symptoms of unknown origin in whom WD was considered in the differential diagnosis. Although a strong correlation of ceruloplasmin protein concentration with oxidase activity was observed in controls, this was not the case for these patients. Twelve patients, presenting with various types of hepatic disease, demonstrated a weak correlation between ceruloplasmin protein concentration and oxidase activity. Ten percent of patients with neurologic symptoms ( n = 41) had low ceruloplasmin concentrations and oxidase activity, and another 8% had normal ceruloplasmin concentrations associated with low oxidase activity. Although the enzymatic method is preferred for its biologic relevance, ceruloplasmin analysis is not a reliable diagnostic parameter for the diagnosis of WD in patients with liver disease. An important use of the ceruloplasmin oxidase assay is in the follow-up of patients with WD. Ceruloplasmin oxidase activity was undetectable in sera from patients with WD who were undergoing long-term chelation therapy, suggesting an early sign of copper depletion and a need for subsequent monitoring for symptoms of copper deficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15614251     DOI: 10.1016/j.lab.2004.08.005

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  8 in total

Review 1.  New tools for Wilson's disease diagnosis: exchangeable copper fraction.

Authors:  France Woimant; Nouzha Djebrani-Oussedik; Aurélia Poujois
Journal:  Ann Transl Med       Date:  2019-04

2.  Decreased plasma levels of ceruloplasmin after diet-induced weight loss in obese women.

Authors:  N Tajik; A Golpaie; S A Keshavarz; M Djalali; M Sehat; F Masoudkabir; Z Ahmadivand; F Fatehi; M Zare; T Yazdani
Journal:  J Endocrinol Invest       Date:  2011-07-27       Impact factor: 4.256

3.  Is elevated serum ceruloplasmin level associated with increased risk of coronary artery disease?

Authors:  Ayşe Yeşim Göçmen; Emel Sahin; Ender Semiz; Saadet Gümuşlü
Journal:  Can J Cardiol       Date:  2008-03       Impact factor: 5.223

4.  Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson's disease and in hepatic encephalopathy.

Authors:  Mariacristina Siotto; Patrizio Pasqualetti; Massimo Marano; Rosanna Squitti
Journal:  J Neural Transm (Vienna)       Date:  2014-03-25       Impact factor: 3.575

Review 5.  Therapeutic strategies in Wilson disease: pathophysiology and mode of action.

Authors:  Wolfgang Stremmel; Ralf Weiskirchen
Journal:  Ann Transl Med       Date:  2021-04

6.  Ceruloplasmin and Hypoferremia: Studies in Burn and Non-Burn Trauma Patients.

Authors:  Michael A Dubick; Johnny L Barr; Carl L Keen; James L Atkins
Journal:  Antioxidants (Basel)       Date:  2015-03-06

Review 7.  Update on the clinical management of Wilson's disease.

Authors:  Peter Hedera
Journal:  Appl Clin Genet       Date:  2017-01-13

8.  Characterization of Fibrinogen as a Key Modulator in Patients with Wilson's Diseases with Functional Proteomic Tools.

Authors:  Pei-Wen Wang; Tung-Yi Lin; Yu-Chiang Hung; Wen-Neng Chang; Pei-Ming Yang; Mu-Hong Chen; Chau-Ting Yeh; Tai-Long Pan
Journal:  Int J Mol Sci       Date:  2019-09-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.